The Analysis, Interpretation, and Presentation of Quality of Life Data
暂无分享,去创建一个
[1] P. Fayers,et al. Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff , 1998, Quality of Life Research.
[2] M. King. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 , 1996, Quality of Life Research.
[3] D. L. Fairclough,et al. Functional Assessment of Cancer Therapy (FACT-G): Non-response to individual questions , 1996, Quality of Life Research.
[4] R. Stephens,et al. Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial , 1994, Quality of Life Research.
[5] Robert Milroy,et al. O-179 The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting , 2003 .
[6] Napp,et al. The big lung trial (BLT): Determining the value of cisplatin- based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting , 2002 .
[7] N. Aaronson,et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] P. Fayers,et al. Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. , 2000, Statistics in medicine.
[9] G. Molenberghs,et al. Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. , 2000, European journal of cancer.
[10] F D Wolinsky,et al. Identifying meaningful intra-individual change standards for health-related quality of life measures. , 2000, Journal of evaluation in clinical practice.
[11] M. Parmar,et al. Patient-reported short-term and long-term physical and psychologic symptoms; results of the continuous hyperfractionated accelerated radiotherapy (CHART). Randomized trial in non-small-cell lung cancer , 1999 .
[12] R. Stephens,et al. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise , 1999, British Journal of Cancer.
[13] R. Stephens,et al. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Machin,et al. Suggestions for the presentation of quality of life data from clinical trials. , 1998, Statistics in medicine.
[15] D Machin,et al. Incomplete quality of life data in randomized trials: missing items. , 1998, Statistics in medicine.
[16] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Parmar,et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.
[18] H. Burris,et al. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. , 1997, European journal of cancer.
[19] D. Girling. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial , 1996, The Lancet.
[20] D. Machin,et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. , 1996, British Journal of Cancer.
[21] R. Sanderman. Measuring the quality of life of cancer patients with the Rotterdam Symptom Checklist (RSCL): a manual , 1996 .
[22] D. Girling,et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).
[23] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[24] R. Kaplan. Quality of life assessment for cost/utility studies in cancer. , 1993, Cancer treatment reviews.
[25] F. Cavalli,et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] D. Osoba,et al. Quality-of-life assessment: patient compliance with questionnaire completion. , 1992, Journal of the National Cancer Institute.
[27] D. Osoba,et al. Quality of life assessment: Patient compliance with questionnaire completion , 1991 .
[28] P. Fayers,et al. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. , 1991, British Journal of Cancer.
[29] P Glasziou,et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.
[31] R. Gelber,et al. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.